help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neely, S. M.
Right arrow Articles by Ts'ao, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neely, S. M.
Right arrow Articles by Ts'ao, C. H.

American Journal of Pathology, Vol 115, 390-396, Copyright © 1984 by American Society for Investigative Pathology

REGULAR ARTICLES

Effect of hematin on endothelial cells and endothelial cell-platelet interactions

SM Neely, DV Gardner, D Green and CH Ts'ao

Hematin, a therapeutic agent for acute porphyrias, induces a coagulopathy characterized by thrombocytopenia and prolonged clotting times. In vitro, it activates platelets and inhibits thrombin and plasmin. Hematin has also been shown to participate in the activation of microsomal cyclooxygenase. The apparent diversity of hematin's effects on multiple hemostatic components as well as its role in prostaglandin synthesis led the authors to investigate the effects of hematin on endothelial cells and endothelial cell-platelet interactions. Marked morphologic alterations of cultured bovine aortic endothelial cells ( BAECs ) were noted after exposure to as little as 2 micrograms/ml hematin in HEPES buffer or to 40 micrograms/ml of hematin in plasma (a level achieved during hematin therapy). These changes included cell retraction and surface vesiculation. Despite the apparent severity of the changes, there was no associated cell lysis or detachment. Furthermore, the cells resumed their cobblestone appearance after hematin had been removed. Platelet adhesion to hematin-treated monolayers was significantly increased, especially when low concentrations of hematin were included in the platelet suspensions. Prostacyclin production was not increased by BAECs exposed to hematin, presumably because of the inaccessibility of hematin to cyclooxygenase in intact cells. The endothelial changes observed in tissue culture are consistent with the clinical observations of phlebitis at the injection site and provide an additional explanation for the thrombocytopenia in patients receiving hematin therapy.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by the American Society for Investigative Pathology.